Technology

Nymox Pharmaceuticals

$2.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-3.80%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell NYMX and other stocks, options, and ETFs commission-free!

About NYMX

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas. The listed name for NYMX is Nymox Pharmaceutical Corporation Common Stock (Bahamas).

CEO
Paul Averback
Employees
4
Headquarters
Nassau, New Providence
Founded
1995
Market Cap
176.77M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
125.79K
High Today
$2.35
Low Today
$2.15
Open Price
$2.30
Volume
193.30K
52 Week High
$4.79
52 Week Low
$1.66

Collections

NYMX Earnings

-$0.08
-$0.05
-$0.03
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 29, After Hours

You May Also Like

EFSC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure